BD Kiestra
Advancing the world of health by improving medical discovery, diagnostics and the delivery of care.
Launch date
Market cap
€61.9b
Enterprise valuation
€74.6b (Public information from Sep 2024)
Share price
$231.59 BDX
Eysins Canton of Vaud (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 17.3b | 17.1b | 20.2b | 18.9b | 19.4b | 20.1b | 21.4b |
| % growth | 8 % | (1 %) | 18 % | (7 %) | 3 % | 4 % | 6 % |
| EBITDA | 4.1b | 4.0b | 5.2b | 4.6b | 4.7b | - | - |
| % EBITDA margin | 24 % | 23 % | 26 % | 24 % | 24 % | - | - |
| Profit | 1.2b | 874m | 2.1b | 1.8b | 1.5b | - | - |
| % profit margin | 7 % | 5 % | 10 % | 9 % | 8 % | - | - |
| R&D budget | 1.1b | 1.1b | 1.3b | 1.3b | 1.2b | - | - |
| R&D % of revenue | 6 % | 6 % | 7 % | 7 % | 6 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
€420k | Grant | ||
N/A | Acquisition | ||
| Total Funding | €420k | ||